NCT00482599View on ClinicalTrials.gov

Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2005

Primary Completion Date

April 13, 2006

Study Completion Date

April 13, 2006

Conditions
Anesthesia, General
Interventions
DRUG

Sugammadex

2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00482599 - Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED) | Biotech Hunter | Biotech Hunter